BioSpace News Archive

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a change to its 2020 Annual Meeting of Stockholders

Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has obtained TSX-V approval to issue 16,760,000 common shares of the Company to settle outstanding debt.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced the pricing of its private offering of $250 million aggregate principal amount of 2.75% Convertible Senior Notes due 2027.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 2,826,088 shares of its common stock at a public offering price of $23.00 per share.

BioSig Technologies, Inc. and its subsidiary, ViralClear Pharmaceuticals, Inc., announced a reminder that it will host a call to discuss the Phase II clinical trials of merimepodib, its broad-spectrum oral anti-viral candidate for the treatment of COVID-19 in adult patients.

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Krish S. Krishnan, chairman and chief executive officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast taking place June 9-11, 2020.

Novavax, Inc. (NASDAQ: NVAX), today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at 11:30 a.m. EDT, the panel will discuss COVID-19 vaccines.

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020.

Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10 at 4:40 PM EDT, and to participate in the Raymond James Human Health Innovation Conference on June 18, 2020.